ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023

Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.

Gavin GiovannoniPubMed ↗Publisher ↗

No numbers read from the abstract.